Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves Semaglutide for Type 2 Diabetes

Novo Nordisk news release; 2017 Dec 5

The FDA has approved Ozempic (semaglutide) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Indications: Ozempic is a glucagon-like peptide 1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dosage and administration: Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly. Administer once weekly at any time of day, with or without meals.

Efficacy and safety: Approval is based on results from a Phase 3a clinical trial program, where Ozempic produced clinically meaningful and statistically significant reductions in A1c compared with placebo, sitagliptin, and exenatide extended-release. It also resulted in reduced body weight.

Side effects/risks: The most common adverse reactions are nausea, vomiting, diarrhea, abdominal pain, and constipation.

Citation:

Novo Nordisk receives FDA approval of Ozempic (semaglutide) injection for the treatment of adults with type 2 diabetes. [news release]. Plainsboro, NJ: Novo Nordisk A/S. December 5, 2017. https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-appro.... Accessed December 6, 2017.

Ozempic [package insert]. Plainsboro, NJ: Novo Nordisk A/S. 2017. http://www.novo-pi.com/ozempic.pdf. Accessed December 6, 2017.

This Week's Must Reads

Weight-Loss Efforts in Endometrial Ca Survivors, Cochrane; 2018 Feb 1; Kitson, Ryan, et al

Sulfonylureas and Cardiac Outcomes Evaluated, Diabetes Care; ePub 2018 Feb 2; Leonard, et al

What Impacts Children’s Attempts to Lose Weight? , Obesity; ePub 2018 Feb 1; Ling, Stommel, et al

These Patients with T1D Less Apt to Experience CVD, Diabetes Care; ePub 2018, Jan 31; Gordin, et al

Activity, BMI, and Clustered Metabolic Risk , Metab Syndr Relat Disord; ePub 2018 Jan 29; Williams, et al

Must Reads in Diabetes

Sulfonylureas and Cardiac Outcomes Evaluated, Diabetes Care; ePub 2018 Feb 2; Leonard, et al

These Patients with T1D Less Apt to Experience CVD, Diabetes Care; ePub 2018, Jan 31; Gordin, et al

How Insurance Plans Impact Diabetes Outcomes , Diabetes Care; ePub 2018 Jan 30; Wharam, et al

Improving Diet Without Causing Eating Disorders , Diabetes Care; ePub 2018 Jan 25; Colman, et al

These Patients Prone to Avoidable Hospitalizations, Diabetes Care; ePub 2018, Jan 29; Rubens, et al